Med2Date — Clinical Guidelines
Home Oncology Bladder Cancer

Bladder Cancer

Last updated 31 May 2026 · Oncology clinical guideline

📋 Key Information Summary

📋
  • Bladder cancer is the 8th most common cancer in Australia (~3,100 new cases/year); median age at diagnosis is ~73 years with a male-to-female ratio of approximately 3:1.
  • Urothelial (transitional cell) carcinoma accounts for >90% of cases; squamous cell carcinoma, adenocarcinoma, and small-cell carcinoma are less common.
  • Tobacco smoking is the single greatest modifiable risk factor (attributable fraction 30–50%), followed by occupational aromatic amine exposure.
  • Non-muscle-invasive bladder cancer (NMIBC) — Ta, T1, and carcinoma in situ (CIS) — comprises ~75% of new diagnoses and is managed primarily with transurethral resection (TURBT) ± intravesical therapy.
  • Intravesical BCG (Bacillus Calmette-Guérin) is the gold-standard adjuvant for high-risk NMIBC (high-grade Ta, T1, CIS), reducing progression risk by approximately 30%.
  • Muscle-invasive bladder cancer (MIBC) — ≥T2 — requires radical cystectomy with pelvic lymph-node dissection or trimodality therapy (maximal TURBT + chemoradiation) in appropriately selected patients.
  • Neoadjuvant cisplatin-based combination chemotherapy (e.g., gemcitabine + cisplatin or dose-dense MVAC) before cystectomy improves overall survival by ~5–8% and is recommended for eligible patients.
  • For cisplatin-ineligible patients with advanced/metastatic disease, immune checkpoint inhibitors (pembrolizumab, nivolumab, avelumab) are PBS-authority options.
  • Flexible cystoscopy is the primary surveillance tool for recurrence; urine cytology has high specificity for high-grade disease but limited sensitivity for low-grade tumours.
  • Aboriginal and Torres Strait Islander peoples have a higher proportion of advanced-stage presentation and lower 5-year survival; culturally safe, multidisciplinary care and timely referral are essential.
  • All patients should be discussed at a multidisciplinary team (MDT) meeting for treatment planning, ideally at a designated cancer centre with uro-oncology subspecialty expertise.
  • Urinary tract infections should be excluded before intravesical BCG administration to prevent severe systemic BCGosis.

Introduction & Australian Epidemiology

Bladder cancer is one of the most common urological malignancies in Australia, with approximately 3,100 new diagnoses annually and a lifetime risk of roughly 1 in 30 for men and 1 in 100 for women. It is predominantly urothelial (transitional cell) carcinoma, which accounts for more than 90% of cases in developed countries. The remaining histological subtypes include squamous cell carcinoma (associated with schistosomiasis, chronic catheter use, or chronic infection), adenocarcinoma, and neuroendocrine/small-cell carcinoma.

At presentation, approximately 75% of cases are non-muscle-invasive (stages Ta, T1, and carcinoma in situ [CIS]) and are managed with endoscopic resection and intravesical therapy, while 25% present as muscle-invasive or metastatic disease requiring more aggressive multimodal treatment. The disease carries a significant recurrence risk — up to 70% of NMIBC patients will experience at least one recurrence within five years, and high-grade T1 or CIS tumours have a 20–50% risk of progression to muscle-invasive disease.

Australia-wide, the age-standardised incidence rate is approximately 11.1 per 100,000 for males and 3.2 per 100,000 for females. Bladder cancer contributes approximately 1,000 deaths per year in Australia. The high recurrence and surveillance demands make it one of the most expensive cancers per patient to manage over a lifetime, with cystoscopy, imaging, and intravesical treatments forming the core of ongoing care.

⚠️
Safety alert: Intravesical BCG must never be administered if urinary tract infection is suspected or confirmed. BCG instillation in the presence of mucosal disruption or active infection can lead to life-threatening systemic BCGosis (disseminated mycobacterial infection).

Epidemiology & Risk Factors

Bladder cancer risk is multifactorial. Understanding modifiable risk factors is essential for primary prevention counselling in general practice and at the time of diagnosis.

Modifiable Risk Factors

Risk Factor Attributable Fraction Mechanism / Notes
Cigarette smoking 30–50% Aromatic amines (2-naphthylamine, 4-aminobiphenyl) excreted in urine; risk increases with pack-years; cessation reduces risk by ~30% over 15 years
Occupational exposure 10–20% Aromatic amines in dye, rubber, leather, paint, printing industries; latency 15–40 years
Chronic arsenic exposure <1% Contaminated drinking water; relevant in some regional Australian groundwater sources
Cyclophosphamide / ifosfamide <1% Acrolein metabolite; mesna co-administration is protective

Non-modifiable Risk Factors

  • Age: Median age at diagnosis ~73 years; rare under 40 years.
  • Sex: Male:female ratio approximately 3:1; women tend to present at a more advanced stage.
  • Caucasian ethnicity: Higher incidence in Caucasian populations; ATSI peoples present with more advanced disease.
  • Family history: 1.7-fold increased risk with first-degree relative; twin studies suggest moderate heritability.
  • NAT2 slow acetylator phenotype: Increased susceptibility to aromatic amine carcinogenesis.
  • Schistosomiasis: Major risk factor for squamous cell carcinoma; relevant in migrants from endemic regions.
  • Chronic indwelling catheter: Squamous cell metaplasia and SCC risk, particularly in spinal-cord-injured patients.

Pathology & Classification

Histological Subtypes

Subtype Frequency Key Features
Urothelial (transitional cell) carcinoma >90% Arises from urothelium; papillary (Ta) or flat (CIS); molecular subtypes luminal, basal, neuronal
Squamous cell carcinoma 3–5% Associated with schistosomiasis, chronic irritation, indwelling catheters; typically invasive at diagnosis
Adenocarcinoma 1–2% Urachal (dome/anterior wall) or non-urachal; mucin-producing
Small-cell neuroendocrine carcinoma <1% Highly aggressive; managed with platinum-etoposide chemotherapy similar to small-cell lung cancer

WHO/ISUP Grading (2016)

  • Papillary urothelial neoplasm of low malignant potential (PUNLMP): Low recurrence, minimal progression risk.
  • Low-grade papillary urothelial carcinoma: Well-differentiated; low progression risk but high recurrence.
  • High-grade papillary urothelial carcinoma: Poorly differentiated; significant progression and metastatic risk.
  • Carcinoma in situ (CIS): Flat, high-grade intraepithelial neoplasia; considered a high-risk precursor with ~50–75% progression if untreated.

Molecular Classification

The TCGA molecular subtypes (Luminal, Luminal-papillary, Basal/Squamous, Neuronal, Stroma-rich) are increasingly used to predict response to neoadjuvant chemotherapy and immunotherapy. Luminal tumours may respond better to FGFR-targeted therapies (erdafitinib), while basal/squamous tumours tend to be more responsive to cisplatin-based chemotherapy. This classification is not yet standard of care in Australia but is available at select tertiary centres.

Staging & Cystoscopy

TNM Staging (AJCC 8th Edition)

Non-Invasive
Ta / CIS
Ta: Non-invasive papillary carcinoma confined to mucosa. CIS: Flat high-grade intraepithelial neoplasia.
Setting: Urology outpatient — TURBT + intravesical therapy
Lamina Propria
T1
Tumour invades lamina propria (subepithelial connective tissue) but not muscularis propria.
Setting: Urology — re-TURBT in 4–6 weeks + intravesical BCG if high-grade
Muscle Invasive
T2+
T2: Invades muscularis propria (detrusor). T3: Perivesical fat. T4: Adjacent organs/pelvic sidewall. N+: Regional nodes. M1: Distant metastases.
Setting: MDT — radical cystectomy or trimodality therapy ± neoadjuvant chemotherapy

Cystoscopy

White-light flexible cystoscopy remains the gold standard for initial diagnosis and recurrence surveillance. It is performed under local anaesthesia (instillation lidocaine gel 2%) in outpatient settings. At the time of TURBT, the following adjuncts are available at Australian centres:

  • Narrow-band imaging (NBI): Enhances mucosal vascular pattern; improves CIS and flat lesion detection; available at most tertiary centres.
  • Photodynamic diagnosis / Blue-light cystoscopy (hexaminolevulinate): Fluorescence-guided detection; significantly improves detection of CIS (sensitivity >90% vs ~70% white light); available at select centres (MBS item-specific considerations).
  • Enhanced cystoscopy (Storz Professional Image Enhancement System — SPIES): Digital post-processing contrast enhancement; growing uptake.

Cross-Sectional Imaging

Essential
CT urogram (abdomen/pelvis with contrast)
Primary staging investigation; assesses upper tracts, lymphadenopathy, distant metastases. MBS item applicable.
Available
Multiparametric MRI pelvis
Increasingly used for local staging of MIBC, particularly to differentiate T2 from T3; avoids ionising radiation.
Available
PET-CT (¹⁸F-FDG or ¹⁸F-PSMA)
Role in nodal and metastatic staging is evolving; not yet standard of care; available at tertiary centres.

Urinary Biomarkers

Test Sensitivity Specificity Role
Urine cytology 40–60% 90–95% High specificity for high-grade/CIS; limited for low-grade
NMP22 (Nuclear Matrix Protein 22) ~70% ~80% Adjunct; higher false-positive rate; not funded in routine Australian practice
UroVysion FISH ~70% ~85% Detects aneuploidy; useful in equivocal cytology; limited availability in Australia

Management: TURBT, BCG, Cystectomy & Chemotherapy

A. Transurethral Resection of Bladder Tumour (TURBT)

TURBT is the cornerstone of diagnosis and treatment for NMIBC. The goals are complete tumour resection, accurate staging, and provision of adequate tissue for pathological assessment.

  • Standard TURBT: Monopolar or bipolar resection in saline; specimen should include detrusor muscle to confirm staging.
  • Re-TURBT (second-look): Recommended 4–6 weeks after initial TURBT for all T1 tumours, incomplete initial resection, absence of detrusor muscle in the specimen, or high-grade Ta disease. Upstaging to T2 occurs in ~25% of T1 cases at re-TURBT.
  • Single immediate post-operative intravesical chemotherapy: Mitomycin C 40 mg or gemcitabine 2,000 mg in 50 mL saline, instilled within 24 hours (ideally within 6 hours) of TURBT for low-intermediate risk tumours. Reduces recurrence by ~35%. MBS/PBS considerations apply.

B. Intravesical BCG (Bacillus Calmette-Guérin)

Intravesical BCG is the standard adjuvant therapy for high-risk NMIBC. The Australian BCG strain used is typically the Danish 1331 strain (Immunocyst® or OncoTICE®).

💊
BCG (Intravesical)
OncoTICE® / Immunocyst® · Live attenuated mycobacterium
Induction dose 1 vial (1–8 × 10⁸ CFU) in 50 mL normal saline, intravesical instillation, weekly × 6 weeks
Maintenance dose 3 weekly instillations at 3, 6, 12, 18, 24, 30 and 36 months (full Lamm protocol)
Retention time 2 hours in bladder if tolerated; reposition every 15 min for mucosal contact
Contraindications UTI, visible haematuria, traumatic catheterisation, immunosuppression, prior BCG sepsis, pregnancy
Renal adjustment None required (intravesical route)
PBS status Restricted Benefit — Authority Required
⚠️
BCG toxicity management: Mild local symptoms (dysuria, frequency, haematuria) are common. For moderate-severe BCG-induced cystitis, use isoniazid 300 mg daily PO. For systemic BCGosis (fever, rigors, pneumonitis, hepatitis), commence triple anti-tuberculous therapy: isoniazid 300 mg + rifampicin 600 mg + ethambutol 15 mg/kg daily PO; add prednisolone 25–40 mg daily for severe cases. Consult infectious diseases urgently.

C. Alternative Intravesical Agents (BCG-Unresponsive or BCG-Shortage)

💊
Intravesical Mitomycin C
Mutamycin® · Alkylating agent
Dose 40 mg in 40–50 mL sterile water, intravesical, weekly × 6–8 weeks induction; monthly maintenance optional
PBS status Restricted Benefit — Authority Required
💊
Intravesical Gemcitabine
Gemzar® · Antimetabolite
Dose 2,000 mg in 50–100 mL saline, intravesical, weekly × 6 weeks; alternative for BCG-unresponsive disease
PBS status Restricted Benefit — Authority Required

D. Radical Cystectomy

Radical cystectomy with bilateral pelvic lymph-node dissection (PLND) is the gold-standard treatment for MIBC and BCG-unresponsive high-risk NMIBC. Extended PLND (up to the aortic bifurcation) is recommended.

Urinary Diversion Type Advantages Considerations
Ileal conduit (Bricker) Incontinent Shorter operative time; lower complication rate; most common in Australia Stoma care; appliance required
Orthotopic neobladder (Studer/ Hautmann) Continent Voiding per urethra; body image benefit Requires good renal function, urethral margin negative; CIC may be needed
Continent cutaneous diversion (Mainz pouch II) Continent No external appliance; catheterisable stoma Higher complication rate; less commonly performed

Robotic-assisted laparoscopic cystectomy is increasingly performed at major Australian centres with comparable oncological outcomes to open surgery and potential benefits in blood loss and recovery time.

E. Chemotherapy — Neoadjuvant & Adjuvant

Neoadjuvant Cisplatin-Based Chemotherapy (NAC)

NAC before radical cystectomy improves absolute overall survival by approximately 5–8% (level 1 evidence). It is recommended for all eligible patients with MIBC (cT2–T4a, N0–N1) with adequate renal function (GFR ≥ 60 mL/min). Two standard regimens are used in Australia:

💊
Gemcitabine + Cisplatin (GC)
Gemzar® + Platinol® · 1st-line NAC regimen
Regimen Gemcitabine 1,000 mg/m² IV D1,8 + Cisplatin 70 mg/m² IV D1; q21 days × 4 cycles
Renal adjustment Contraindicated if CrCl <60 mL/min; carboplatin substitution (AUC 5) if borderline renal function
PBS status ✔ PBS General Benefit
💊
Dose-dense MVAC (dd-MVAC)
Methotrexate · Vinblastine · Doxorubicin · Cisplatin · 2nd-line NAC regimen
Regimen Methotrexate 30 mg/m² D1 + Vinblastine 3 mg/m² D2 + Doxorubicin 30 mg/m² D2 + Cisplatin 70 mg/m² D2; q14 days with G-CSF × 4 cycles
Key note Higher response rate than standard MVAC with less toxicity; requires G-CSF support
PBS status ✔ PBS General Benefit

Adjuvant Chemotherapy

Adjuvant cisplatin-based chemotherapy is recommended for patients with pT3/T4 and/or N+ disease who did not receive neoadjuvant chemotherapy. The evidence base is weaker than for NAC, and this approach is generally reserved for patients with adequate post-operative renal function.

F. Trimodality Therapy (TMT)

Maximal TURBT + concurrent chemoradiation is an established bladder-sparing alternative to radical cystectomy for MIBC in carefully selected patients. It preserves the native bladder in approximately 40–60% of patients at 5 years.

  • Radiation: 64 Gy in 32 fractions (or hypofractionated 55 Gy in 20 fractions) to bladder ± pelvic nodes.
  • Radiosensitiser: Cisplatin (preferred) or 5-fluorouracil + mitomycin C (for cisplatin-ineligible patients).
  • Selection criteria: Solitary tumour <5 cm, no CIS, complete TURBT achievable, no hydronephrosis, adequate bladder capacity.

G. Systemic Therapy for Advanced / Metastatic Disease

Line Regimen Key Eligibility PBS Status
1st line — cisplatin-fit GC or dd-MVAC (as above) GFR ≥ 60 mL/min, ECOG 0–1 ✔ PBS General Benefit
1st line — cisplatin-unfit Carboplatin AUC 5 + Gemcitabine GFR 30–59 mL/min; poor performance status; comorbidities ✔ PBS General Benefit
1st line maintenance Avelumab 10 mg/kg IV q2w No progression after platinum-based 1L; PD-L1 ≥ 1% (CPS) Authority Required — Specialist
2nd line Pembrolizumab 200 mg IV q3w Progression on/after platinum-based chemotherapy Authority Required — Specialist
2nd line (post-CIS) Nivolumab 240 mg IV q2w Progression on/after platinum-based chemotherapy Authority Required — Specialist
FGFR-targeted Erdafitinib 8 mg PO daily (titrate to 9 mg if FGFR3/2 mutation) FGFR3/2 alteration detected; locally advanced or metastatic; post-platinum and post-PD-1/PD-L1 Not PBS-listed (as of 2024)
✅
MDT discussion: All patients with confirmed MIBC or metastatic bladder cancer should be discussed at a uro-oncology MDT meeting prior to treatment initiation. This ensures optimal sequencing of surgery, chemotherapy, immunotherapy, and radiation.

Monitoring & Surveillance

NMIBC Surveillance (Post-TURBT)

3 months
First surveillance cystoscopy + urine cytology. Re-TURBT if initial was high-risk T1.
3–6 monthly (Years 1–2)
Cystoscopy ± cytology for high-risk NMIBC; every 6 months for intermediate risk.
6–12 monthly (Years 3–5)
Cystoscopy interval extended if no recurrence. Annual upper tract imaging (CT urogram) for high-risk.
Annually (Year 5+)
Lifelong cystoscopy recommended for high-risk disease. Intermediate risk may step down to 2-yearly.

MIBC Surveillance (Post-Cystectomy)

  • CT chest/abdomen/pelvis every 6 months for 2 years, then annually for 5 years.
  • Urethral wash cytology (if urethra-sparing) every 6–12 months.
  • Monitor renal function (creatinine, eGFR) and B12 levels annually (ileal conduit/neobladder).
  • Upper tract imaging if new haematuria or symptoms of ureteric recurrence.

Special Populations

🤰 Pregnancy
Incidence: Extremely rare in pregnancy; most are low-grade Ta tumours.
Management: TURBT may be performed in the 2nd trimester with obstetric team involvement; intravesical therapies contraindicated in pregnancy.
Note: Persistent haematuria in pregnancy warrants investigation; coordinate with obstetrics and urology MDT.
👶 Paediatrics
Rarity: Bladder cancer is exceedingly rare in children (<18 years); rhabdomyosarcoma is the more common bladder tumour in paediatric age.
Management: Refer to paediatric oncology MDT; treat at a designated paediatric cancer centre.
👴 Elderly
Considerations: Median age ~73; many patients are frail or have significant comorbidities.
Cystectomy: Robotic approach may offer recovery benefit; ileal conduit preferred over neobladder in elderly.
Immunotherapy: Checkpoint inhibitors generally well tolerated in elderly; no age-specific dose adjustments.
Cisplatin: Assess GFR carefully; carboplatin substitution if GFR <60 mL/min.
🫘 Renal Impairment
Cisplatin: Contraindicated if CrCl <60 mL/min; substitute with carboplatin AUC 5.
Intravesical agents: No renal dose adjustments required (local absorption minimal).
Neobladder: Avoid in patients with CKD Stage ≥3b (eGFR <45) — ileal conduit preferred.
🫁 Hepatic Impairment
Gemcitabine: Reduce dose or avoid in significant hepatic dysfunction (bilirubin >2× ULN).
Immunotherapy: Pembrolizumab and nivolumab can be used with mild hepatic impairment; avoid in severe liver disease.
🛡️ Immunocompromised
BCG: Contraindicated in patients with HIV (CD4 <200), active immunosuppressive therapy, or organ transplant recipients.
Alternative: Intravesical mitomycin C or gemcitabine for high-risk NMIBC.
Checkpoint inhibitors: Generally avoided in patients on transplant immunosuppression due to rejection risk.

Aboriginal and Torres Strait Islander Health Considerations

Aboriginal and Torres Strait Islander Health
Epidemiology
ATSI Australians have a higher proportion of bladder cancers diagnosed at advanced stage and have lower 5-year survival rates compared to non-Indigenous Australians (AIHW, 2023). Smoking prevalence is approximately 2.5× higher in ATSI populations, which is the primary driver of the increased attributable risk.
Geographic access
Many ATSI patients reside in remote or very remote areas where access to urology subspecialists, cystoscopy services, and MDT meetings is limited. RFDS and telehealth consultations may facilitate initial assessment and ongoing surveillance. Patients requiring radical cystectomy or intravesical BCG must travel to metropolitan centres.
Cultural safety
Discuss urinary symptoms, stoma care, and body-image issues in a culturally safe context. Engage Aboriginal Health Workers and Liaison Officers in the care team. Respect kinship obligations and allow family members to be present during consultations where appropriate.
Comorbidities
Higher prevalence of diabetes, CKD, and cardiovascular disease may limit cisplatin eligibility and increase surgical risk. Pre-operative optimisation should involve a multidisciplinary team including ATSI health practitioners.
Tobacco cessation
Smoking cessation is a critical intervention for both primary prevention and improved treatment outcomes. Refer to Tackling Indigenous Smoking programmes and Quitline (13 7848). Nicotine replacement therapy is PBS-listed and available through Closing the Gap PBS co-payment arrangements.
Follow-up and retention
Lifelong cystoscopy surveillance is essential for NMIBC. Flexible scheduling, patient navigation programmes, and integration with Aboriginal Community Controlled Health Organisations (ACCHOs) improve follow-up adherence. Telehealth review between cystoscopy visits can maintain engagement.

📚 References

  1. 1. Australian Institute of Health and Welfare (AIHW). Cancer data in Australia. Canberra: AIHW; 2023. Available from: https://www.aihw.gov.au/reports/cancer/cancer-data-in-australia
  2. 2. Babjuk M, Burger M, Capoun O, et al. European Association of Urology Guidelines on Non-muscle-invasive Bladder Cancer (Ta, T1, and CIS). Eur Urol. 2022;81(1):75–94.
  3. 3. Witjes JA, Bruins HM, Cathomas R, et al. European Association of Urology Guidelines on Muscle-invasive and Metastatic Bladder Cancer. Eur Urol. 2021;79(6):823–845.
  4. 4. Grossman HB, Natale RB, Tangen CM, et al. Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer. N Engl J Med. 2003;349(9):859–866.
  5. 5. Lamm DL, Blumenstein BA, Crissman JD, et al. Maintenance bacillus Calmette-Guérin immunotherapy for recurrent TA, T1 and carcinoma in situ transitional cell carcinoma of the bladder: a randomized Southwest Oncology Group Study. J Urol. 2000;163(4):1124–1129.
  6. 6. von der Maase H, Hansen SW, Roberts JT, et al. Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study. J Clin Oncol. 2000;18(17):3068–3077.
  7. 7. Powles T, Park SH, Voog E, et al. Avelumab maintenance therapy for advanced or metastatic urothelial carcinoma. N Engl J Med. 2020;383(13):1218–1230.
  8. 8. Bellmunt J, de Wit R, Vaughn DJ, et al. Pembrolizumab as second-line therapy for advanced urothelial carcinoma. N Engl J Med. 2017;376(11):1015–1026.
  9. 9. Cancer Council Australia. Clinical practice guidelines for the management of bladder cancer. Sydney: Cancer Council Australia; 2022.
  10. 10. Royal Australian College of General Practitioners (RACGP). Smoking cessation guidelines for Australian general practice. East Melbourne: RACGP; 2021.
  11. 11. Australian Institute of Health and Welfare (AIHW). Aboriginal and Torres Strait Islander health performance framework 2020 summary report. Canberra: AIHW; 2020.
  12. 12. National Health and Medical Research Council (NHMRC). National statement on ethical conduct in human research. Canberra: NHMRC; 2023 (updated).
for PBS-listed medicines at participating pharmacies.
Cultural safety
Engagement with Aboriginal Community Controlled Health Organisations (ACCHOs) is essential. Cultural safety training for non-Indigenous clinicians, use of Aboriginal Health Workers and Liaison Officers, and incorporation of traditional healing practices alongside Western medicine improve treatment adherence and outcomes. Avoidance of eye contact, respect for gender-sensitive examination practices, and understanding of sorry business protocols are critical elements of culturally safe care.
Medication adherence
Complex DMARD regimens with frequent monitoring requirements present adherence challenges. Long-acting depot injections (e.g., methotrexate SC) may improve adherence compared to oral regimens. Community pharmacy partnerships through the Indigenous Pharmacy Programmes improve medication management.
Specific conditions
Rheumatic heart disease (RHD) requires secondary prophylaxis with benzathine penicillin G (BPG) 1.2 MU IM every 3–4 weeks for a minimum of 10 years or until age 21 (whichever is longer). RHD registers (e.g., NT RHD Register) facilitate recall and follow-up. The Australian RHD Endgame Strategy targets elimination by 2031.
Referral pathways
Referral through ACCHOs and Aboriginal Hospital Liaison Officers (AHLOs) improves engagement. The Specialist Outreach Assistance Programme provides funded specialist visits to remote communities. NT, WA, and QLD have specific rheumatology outreach programmes targeting Indigenous communities.

📚 References

  1. 1. Australian Institute of Health and Welfare (AIHW). Autoimmune disease in Australia. Cat. no. PHE 312. Canberra: AIHW; 2023.
  2. 2. Fraenkel L, Bathon JM, England BR, et al. 2021 American College of Rheumatology guideline for the treatment of rheumatoid arthritis. Arthritis Care Res. 2021;73(7):924–939.
  3. 3. Fanouriakis A, Kostopoulou M, Alber K, et al. 2019 update of the EULAR recommendations for the management of systemic lupus erythematosus. Ann Rheum Dis. 2019;78(6):736–745.
  4. 4. Chung SA, Langford CA, Maz M, et al. 2021 American College of Rheumatology/Vasculitis Foundation guideline for the management of antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Care Res. 2021;73(11):1583–1599.
  5. 5. Smolen JS, Landewé RBM, Bijlsma JWJ, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update. Ann Rheum Dis. 2023;82(1):3–18.
  6. 6. Australian Technical Advisory Group on Immunisation (ATAGI). Australian Immunisation Handbook. Australian Government Department of Health; 2024. Available from: immunisationhandbook.health.gov.au.
  7. 7. Rheumatic Heart Disease Australia (RHDAustralia). The 2020 Australian guideline for prevention, diagnosis, and management of acute rheumatic fever and rheumatic heart disease. 3rd ed. Darwin: Menzies School of Health Research; 2020.
  8. 8. Pharmaceutical Benefits Scheme (PBS). PBS Schedule. Australian Government Department of Health. Available from: pbs.gov.au. Accessed 2024.
  9. 9. Agarwal S, Cunnington J, Nossent J. Autoimmune disease in Indigenous Australians: a systematic review. Int J Rheum Dis. 2021;24(12):1487–1498.
  10. 10. Pisetsky DS. Antinuclear antibody testing — misunderstood or misused? Clin Immunol. 2023;255:109717.
  11. 11. Bertsias GK, Tektonidou M, Amoura Z, et al. Joint European League Against Rheumatism and European Renal Association–European Dialysis and Transplant Association (EULAR/ERA-EDTA) recommendations for the management of adult and paediatric lupus nephritis. Ann Rheum Dis. 2012;71(11):1771–1782.
  12. 12. Ledingham J, Deighton C; British Society for Rheumatology Standards, Audit and Guidelines Working Group. Update on the British Society for Rheumatology guidelines for prescribing TNFα blockers in adults with rheumatoid arthritis. Rheumatology. 2005;44(2):155–158.
  13. 13. National Health and Medical Research Council (NHMRC). National statement on ethical conduct in human research. Canberra: NHMRC; 2023 (updated).
for PBS-listed medicines at participating pharmacies.
Cultural safety
Engagement with Aboriginal Community Controlled Health Organisations (ACCHOs) is essential. Cultural safety training for non-Indigenous clinicians, use of Aboriginal Health Workers and Liaison Officers, and incorporation of traditional healing practices alongside Western medicine improve treatment adherence and outcomes. Avoidance of eye contact, respect for gender-sensitive examination practices, and understanding of sorry business protocols are critical elements of culturally safe care.
Medication adherence
Complex DMARD regimens with frequent monitoring requirements present adherence challenges. Long-acting depot injections (e.g., methotrexate SC) may improve adherence compared to oral regimens. Community pharmacy partnerships through the Indigenous Pharmacy Programmes improve medication management.
Specific conditions
Rheumatic heart disease (RHD) requires secondary prophylaxis with benzathine penicillin G (BPG) 1.2 MU IM every 3–4 weeks for a minimum of 10 years or until age 21 (whichever is longer). RHD registers (e.g., NT RHD Register) facilitate recall and follow-up. The Australian RHD Endgame Strategy targets elimination by 2031.
Referral pathways
Referral through ACCHOs and Aboriginal Hospital Liaison Officers (AHLOs) improves engagement. The Specialist Outreach Assistance Programme provides funded specialist visits to remote communities. NT, WA, and QLD have specific rheumatology outreach programmes targeting Indigenous communities.

📚 References

  1. 1. Australian Institute of Health and Welfare (AIHW). Autoimmune disease in Australia. Cat. no. PHE 312. Canberra: AIHW; 2023.
  2. 2. Fraenkel L, Bathon JM, England BR, et al. 2021 American College of Rheumatology guideline for the treatment of rheumatoid arthritis. Arthritis Care Res. 2021;73(7):924–939.
  3. 3. Fanouriakis A, Kostopoulou M, Alber K, et al. 2019 update of the EULAR recommendations for the management of systemic lupus erythematosus. Ann Rheum Dis. 2019;78(6):736–745.
  4. 4. Chung SA, Langford CA, Maz M, et al. 2021 American College of Rheumatology/Vasculitis Foundation guideline for the management of antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Care Res. 2021;73(11):1583–1599.
  5. 5. Smolen JS, Landewé RBM, Bijlsma JWJ, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update. Ann Rheum Dis. 2023;82(1):3–18.
  6. 6. Australian Technical Advisory Group on Immunisation (ATAGI). Australian Immunisation Handbook. Australian Government Department of Health; 2024. Available from: immunisationhandbook.health.gov.au.
  7. 7. Rheumatic Heart Disease Australia (RHDAustralia). The 2020 Australian guideline for prevention, diagnosis, and management of acute rheumatic fever and rheumatic heart disease. 3rd ed. Darwin: Menzies School of Health Research; 2020.
  8. 8. Pharmaceutical Benefits Scheme (PBS). PBS Schedule. Australian Government Department of Health. Available from: pbs.gov.au. Accessed 2024.
  9. 9. Agarwal S, Cunnington J, Nossent J. Autoimmune disease in Indigenous Australians: a systematic review. Int J Rheum Dis. 2021;24(12):1487–1498.
  10. 10. Pisetsky DS. Antinuclear antibody testing — misunderstood or misused? Clin Immunol. 2023;255:109717.
  11. 11. Bertsias GK, Tektonidou M, Amoura Z, et al. Joint European League Against Rheumatism and European Renal Association–European Dialysis and Transplant Association (EULAR/ERA-EDTA) recommendations for the management of adult and paediatric lupus nephritis. Ann Rheum Dis. 2012;71(11):1771–1782.
  12. 12. Ledingham J, Deighton C; British Society for Rheumatology Standards, Audit and Guidelines Working Group. Update on the British Society for Rheumatology guidelines for prescribing TNFα blockers in adults with rheumatoid arthritis. Rheumatology. 2005;44(2):155–158.
  13. 13. National Health and Medical Research Council (NHMRC). National statement on ethical conduct in human research. Canberra: NHMRC; 2023 (updated).